Enteric Disease Testing Market Report 2026

The enteric disease testing market size has grown strongly in recent years. It will grow from $4.86 billion in 2025 to $5.18 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to waterborne disease outbreaks, food safety concerns, laboratory diagnostic expansion, public health monitoring programs, infectious disease burden.

The enteric disease testing market size is expected to see strong growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rapid test adoption, molecular diagnostic growth, outbreak preparedness initiatives, sanitation awareness, healthcare access expansion. Major trends in the forecast period include rising incidence of foodborne diseases, increased demand for rapid diagnostic tests, expansion of stool-based diagnostic methods, growth in public health surveillance testing, focus on early pathogen identification.

The rising incidence of diarrhea and hemolytic urea syndrome (HUS) is expected to drive the growth of the enteric disease testing market in the coming years. Diarrheal diseases are primarily caused by the consumption of contaminated food and water. Hemolytic urea syndrome (HUS) affects the blood and blood vessels and is most commonly observed in children with diarrhea. Both diarrheal disease and HUS are among the leading causes of death in children under five years of age. The growing prevalence of these conditions increases the need for diagnostic testing solutions, thereby boosting demand for enteric disease testing. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based public health agency, reported that diarrhea causes approximately 443,832 deaths in children under five each year, with an additional 50,851 deaths in children aged 5 to 9 years. Globally, nearly 1.7 billion cases of childhood diarrheal disease occur annually. Therefore, the increasing occurrence of enteric diseases is driving growth in the enteric disease testing market.

Key companies in the enteric disease testing market are developing advanced diagnostic solutions, including laboratory tools, to improve diagnostic accuracy and enhance patient outcomes. Laboratory tools are specialized instruments and equipment used in medical and scientific laboratories to perform tests, analyze samples, and generate reliable diagnostic data. These tools are critical for improving the precision of diagnostic procedures and supporting research across various fields, including enteric disease testing. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co., Ltd., a China-based biotechnology company, launched real-time PCR kits designed specifically for diagnosing gastrointestinal infectious diseases. These kits provide high sensitivity and specificity, enabling the detection of low levels of nucleic acids in diverse samples. They also allow rapid analysis, significantly reducing processing times and increasing throughput in both diagnostic and research applications.

In June 2023, Avacta Group plc, a UK-based provider of diagnostic and life-science technologies, acquired Coris BioConcept SRL for $0.009 billion (£7.4 million) upfront, with an additional earn-out of up to $0.004 billion (£3 million). Through this acquisition, Avacta aims to expand its enteric disease testing portfolio by integrating Coris BioConcept’s rapid lateral-flow and immunochromatographic diagnostic kits for gastrointestinal pathogens, including Giardia, Cryptosporidium, Clostridioides difficile, Helicobacter pylori, rotavirus, and adenovirus. Coris BioConcept SRL, based in Belgium, is a diagnostic manufacturer that provides rapid test kits for gastroenteric infections, respiratory pathogens, and antimicrobial-resistance markers.

Major companies operating in the enteric disease testing market are Becton Dickinson and Company, Biomerica Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Cepheid Inc., Coris Bioconcept, DiaSorin Molecular LLC, MMeridian Life Science Inc., Trinity Biotech plc., Abbott Laboratories, Fisher Scientific Inc., Alere Inc., 3M Company., Asure Quality, Bureau Veritas, Meridian Bioscience Inc., Hologic Inc., Luminex Corporation, Nanosphere Inc., Quidel Corporation, Roche Diagnostics, Siemens Healthcare Diagnostics Inc., Vela Diagnostics, GenMark Diagnostics, BioFire Diagnostics LLC, Veredus Laboratories Pte Ltd.

North America was the largest region in the enteric disease testing market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the enteric disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the enteric disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the enteric disease testing market by increasing costs of imported diagnostic kits, reagents, and laboratory instruments. Hospitals and research laboratories in developed regions are most affected due to dependence on imported testing technologies. These tariffs increase testing costs by raising consumable and equipment expenses, limiting surveillance and routine diagnostics. However, they support domestic diagnostic manufacturing, strengthening regional testing capacity.

The enteric disease testing market research report is one of a series of new reports that provides enteric disease testing market statistics, including enteric disease testing industry global market size, regional shares, competitors with a enteric disease testing market share, detailed enteric disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the enteric disease testing industry. This enteric disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Enteric disease testing is used to diagnose enteric disorders, including food- and water-borne illnesses. These diseases are caused by microorganisms such as viruses, bacteria, and parasites that impact intestinal health. Infection can occur through contaminated food and beverages or contact with the feces of an infected person or animal. Common symptoms of enteric diseases include abdominal cramps, vomiting, nausea, and loss of appetite, which can lead to dehydration and nutrient loss. Enteric disease testing employs various methods and technologies, including diagnostic assays and rapid tests, stool specimen analysis, complete blood count (CBC) tests, blood culture tests, urine tests, antibody tests, and bone marrow tests to identify the causative agents.

The primary disease types in enteric disease testing are bacterial enteric disease, parasitic enteric disease, viral enteric disease, and others. Bacteria are disease-causing microorganisms that are widely present in environments such as soil and water. Examples of enteric bacterial pathogens include Salmonella, Campylobacter, Shigella, Clostridium difficile, and various strains of E. coli. The technologies used for testing include traditional methods, rapid tests, convenience-based assays, polymerase chain reaction (PCR), immunoassays, chromatography, spectrometry, and others. These tests are utilized by hospitals, research centers, clinics, and other healthcare facilities.

The enteric disease testing market includes revenues earned by entities by amebiasis, campylobacteriosis, cryptosporidiosis, and cyclosporiasis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.